IP Library Granted Patent US 12,343,558
Granted Patent B2
US 12,343,558 · App. 17/392,388 · Granted Jul 1, 2025

Method for light-activated drug delivery and system

Inventors: Petteri Uusimaa (Tampere, FI); Robert Perttilä (Tampere, FI); Sallamaari Ylöniemi (Tampere, FI)
Assignee: Modulight, Inc.
A61N5/062A61N2005/0628A61N2005/0662
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,558
App. No.
17/392,388
Granted
Jul 1, 2025
Kind
B2
Abstract

A method and a system for light-activated drug delivery. An optical probe is coupled to a tissue for transmitting light signals to the tissue for actuating and/or monitoring drug delivery with a multi-phase method for drug delivery. A first light signal is transmitted through the optical probe for actuating and/or monitoring the drug delivery and a second light signal having a different wavelength is transmitted, simultaneously with the first light signal, through the optical probe for actuating and/or monitoring the drug delivery.

Claims (38)

1. A method for light-activated drug delivery, the method comprising:

coupling an optical probe to a tissue for transmitting light signals to the tissue for actuating and monitoring drug delivery;

wherein the method is a multi-phase method for drug delivery having two or more sequential actuation and monitoring phases for the drug delivery, the method comprising:

causing a first light signal having a first wavelength to be transmitted through the optical probe for actuating the drug delivery; and

causing a second light signal having a second wavelength to be transmitted, simultaneously with the first light signal, through the optical probe for monitoring the drug delivery, the first wavelength being different from the second wavelength.

2. The method according to claim 1 , wherein the first light signal is transmitted to the tissue and the second light signal is received from the tissue to monitor the arrival of a drug to the tissue.

3. The method according to claim 1 , wherein the first light signal is transmitted to the tissue and the second light signal is received from the tissue to monitor the integrity of a carrier encapsulating a drug for drug delivery.

4. The method according to claim 1 , wherein the first light signal is transmitted to the tissue to actuate the drug delivery by inducing a release of a drug from a carrier and the second light signal is received from the tissue to monitor the release.

5. The method according to claim 1 , wherein the first light signal is transmitted to the tissue to actuate the drug delivery by inducing an activation of a drug and the second light signal is received from the tissue to monitor the activation.

6. The method according to claim 1 , wherein the first light signal is transmitted to the tissue for probing an activation of a drug and the second light signal is received from the tissue for monitoring a completion of the activation of a drug.

7. The method according to claim 1 , wherein the first light signal is transmitted to the tissue to activate fluorescence from a drug and/or a drug-delivery construct encapsulating the drug and the second light signal is received from the tissue to monitor the fluorescence.

8. The method according to claim 1 , wherein the first light signal is transmitted to the tissue to activate characteristic optical response, like fluorescence, reflectance or Raman scattering signal or alike, from the tissue and the second light signal is received from the tissue to monitor the characteristic optical response.

9. The method according to claim 1 , comprising causing one or more signals having a different wavelength to be transmitted simultaneously with the first signal and the second signal through the optical probe for actuating and/or monitoring the drug delivery, the different wavelength being different from the first wavelength and the second wavelength.

10. The method according to claim 1 , wherein two or more different wavelengths are used for actuating drug delivery and/or two or more different wavelengths are used for inducing a monitoring signal.

11. The method according to claim 1 , wherein two or more different wavelengths are used for monitoring drug delivery.

12. A light-activated drug delivery system comprising:

a light source for providing light signals for actuating and monitoring drug delivery;

an optical probe coupled to the light source for transmitting the light signals to a tissue for actuating and monitoring drug delivery and for transmitting light signals from the tissue for monitoring the drug delivery; and

a light receiver coupled to the optical probe for receiving the light signals from the tissue for monitoring the drug delivery;

wherein the system is configured for multi-phase drug delivery with two or more sequential actuation and/or monitoring phases and for:

causing a first light signal having a first wavelength to be transmitted through the optical probe for actuating the drug delivery; and

causing a second light signal having a second wavelength to be transmitted, simultaneously with the first light signal, through the optical probe for monitoring the drug delivery, the first wavelength being different from the second wavelength.

13. The system according to claim 12 , configured to monitor an arrival of a drug to the tissue by transmitting the first light signal to the tissue and receiving the second light signal from the tissue.

14. The system according to claim 12 , configured to monitor the integrity of a carrier encapsulating a drug for drug delivery by transmitting the first light signal to the tissue and receiving the second light signal from the tissue.

15. The system according to claim 12 , configured to:

actuate the drug delivery by transmitting the first light signal to the tissue to induce a release of a drug from a carrier, and

receive the second light signal from the tissue to monitor the release.

16. The system according to claim 12 , configured to:

actuate the drug delivery by transmitting the first light signal to the tissue to induce an activation of a drug, and

receive the second light signal from the tissue to monitor the activation.

17. The system according to claim 12 , configured to monitor completion of activation of a drug by transmitting the first light signal to the tissue and receiving the second light signal from the tissue.

18. The system according to claim 12 , configured to monitor the drug delivery by:

transmitting a first light signal to the tissue to activate fluorescence from a drug and/or a drug-delivery construct, and

receiving the second light signal to monitor the fluorescence.

19. The system according to claim 12 , configured to monitor a characteristic optical response from the tissue by:

transmitting a first light signal to the tissue to induce a characteristic optical response, like fluorescence, reflectance or Raman scattering signal, from the tissue, and

receiving the second light signal to monitor the characteristic optical response from the tissue.

20. The system according to claim 12 , configured for causing one or more signals having a different wavelength to be transmitted simultaneously with the first signal and the second signal through the optical probe for actuating and/or monitoring the drug delivery, the different wavelength being different from the first wavelength and the second wavelength.

Assignments (2)
CHANGE OF NAME Recorded Mar 22, 2022
From: MODULIGHT, INC.
To: MODULIGHT CORPORATION
Reel/Frame 059470/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2021
From: UUSIMAA, PETTERI; PERTTILA, ROBERT; YLONIEMI, SALLAMAARI
To: MODULIGHT, INC.
Reel/Frame 057062/0424 →
Continuity (1)
Related Publication 20230041277A1 · Feb 9, 2023
References Cited (6)
US 10588514B1 · Shang · 2020 [cited by applicant]
US 20160022976A1 · Peyman · 2016 [cited by applicant]
US 20170224205A1 · Sunar · 2017 [cited by examiner]
WO 9906113A1 · 1999 [cited by applicant]
WO 2015089154A1 · 2015 [cited by applicant]
European Patent Office, Written Opinion of the International Searching Authority, dated Oct. 28, 2022, 7 pages. [cited by applicant]